DS
NTLA icon

David Shaw’s Intellia Therapeutics NTLA Stock Holding History

David Shaw’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83,100
Closed -$747K – 4887
2025
Q4 		$747K Buy
+83,100
New +$1.14M ﹤0.01% 3718

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's NTLA Position: Q2 2026 in Review

David Shaw increased its Intellia Therapeutics (NTLA) stake by 12% in Q2 2026, buying an estimated $10M and bringing the position to 6,443,323 shares worth $109M. The position accounts for 0.05% of the portfolio, ranked #418.

David Shaw first reported a position in NTLA in Q4 2019 and has held it in 20 quarters since. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • David Shaw held 6,443,323 shares of Intellia Therapeutics worth $109M as of Q2 2026.
  • David Shaw bought 715,146 Intellia Therapeutics shares in Q2 2026, an estimated $10M.
  • Intellia Therapeutics made up 0.05% of David Shaw's portfolio in Q2 2026, its #418 holding.
  • David Shaw first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.